Terms: = Leukemia AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Clinical Outcome
7 results:
1. Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse.
Onecha E; Rapado I; Luz Morales M; Carreño-Tarragona G; Martinez-Sanchez P; Gutierrez X; Sáchez Pina JM; Linares M; Gallardo M; Martinez-López J; Ayala R
Haematologica; 2021 Sep; 106(9):2325-2333. PubMed ID: 32732356
[TBL] [Abstract] [Full Text] [Related]
2. E2F4 functions as a tumour suppressor in acute myeloid leukaemia via inhibition of the MAPK signalling pathway by binding to ezh2.
Feng Y; Li L; Du Y; Peng X; Chen F
J Cell Mol Med; 2020 Feb; 24(3):2157-2168. PubMed ID: 31943751
[TBL] [Abstract] [Full Text] [Related]
3. High expression of miR-363 predicts poor prognosis and guides treatment selection in acute myeloid leukemia.
Zhang H; Zhang N; Wang R; Shao T; Feng Y; Yao Y; Wu Q; Zhu S; Cao J; Zhang H; Li Z; Liu X; Niu M; Xu K
J Transl Med; 2019 Apr; 17(1):106. PubMed ID: 30935386
[TBL] [Abstract] [Full Text] [Related]
4. Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo.
Wen S; Wang J; Liu P; Li Y; Lu W; Hu Y; Liu J; He Z; Huang P
Cancer Lett; 2018 Jan; 413():35-45. PubMed ID: 29069576
[TBL] [Abstract] [Full Text] [Related]
5. ezh2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitable molecular target in combination treatment approaches.
D'Angelo V; Iannotta A; Ramaglia M; Lombardi A; Zarone MR; Desiderio V; Affinita MC; Pecoraro G; Di Martino M; Indolfi P; Casale F; Caraglia M
J Exp Clin Cancer Res; 2015 Aug; 34(1):83. PubMed ID: 26268310
[TBL] [Abstract] [Full Text] [Related]
6. [Research on molecular markers for epigenetic changes in myeloid malignancies].
Li L; Sun XM
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Dec; 30(6):687-92. PubMed ID: 24327148
[TBL] [Abstract] [Full Text] [Related]
7. The epigenomics revolution in myelodysplasia: a clinico-pathological perspective.
Tan PT; Wei AH
Pathology; 2011 Oct; 43(6):536-46. PubMed ID: 21881538
[TBL] [Abstract] [Full Text] [Related]
